首页> 美国卫生研究院文献>Molecules >Synthesis of 123-Triazolo45-hquinolone Derivatives with Novel Anti-Microbial Properties against Metronidazole Resistant Helicobacter pylori
【2h】

Synthesis of 123-Triazolo45-hquinolone Derivatives with Novel Anti-Microbial Properties against Metronidazole Resistant Helicobacter pylori

机译:具有新型抗甲硝唑抗幽门螺杆菌抗菌性能的123-三唑并45-h喹诺酮衍生物的合成

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Helicobacter pylori infection can lead to gastritis, peptic ulcer, and the development of mucosa associated lymphoid tissue (MALT) lymphoma. Treatment and eradication of H. pylori infection can prevent relapse and accelerate the healing of gastric and duodenal ulcers as well as regression of malignancy. Due to the increasing emergence of antibiotic resistance among clinical isolates of H. pylori, alternative approaches using newly discovered antimicrobial agents in combination with the standard antibiotic regimens for the treatment of H. pylori are of major importance. The purpose of the present study was to investigate the effect of newly synthesized 8-amino 7-substituted fluoroquinolone and their correspondent cyclized triazolo derivatives when either alone or combined with metronidazole against metronidazole-resistant H. pylori. Based on standard antimicrobial susceptibility testing methods and checkerboard titration assay, all of the tested compounds showed interesting antimicrobial activity against 12 clinical strains of H. pylori, with best in vitro effect for compounds >4b and >4c. Fractional inhibitory concentration (FIC) mean values showed synergistic pattern in all compounds of Group 5. In addition, additive activities of some of the tested compounds of Group 4 were observed when combined with metronidazole. In contrast, the tested compounds showed no significant urease inhibition activity. These results support the potential of new fluoroquinolone derivatives to be useful in combination with anti-H. pylori drugs in the management of H. pylori-associated diseases.
机译:幽门螺杆菌感染可导致胃炎,消化性溃疡和粘膜相关淋巴组织(MALT)淋巴瘤的发展。幽门螺杆菌感染的治疗和根除可以预防复发并加速胃和十二指肠溃疡的愈合以及恶性肿瘤的消退。由于幽门螺杆菌临床分离株中越来越多的抗生素耐药性出现,使用新发现的抗菌药物与标准抗生素方案联合治疗幽门螺杆菌的替代方法非常重要。本研究的目的是研究新合成的8-氨基7-取代的氟喹诺酮及其相应的环化三唑衍生物在单独或与甲硝唑联用时对甲硝唑耐药的幽门螺杆菌的作用。根据标准的药敏试验方法和棋盘滴定分析,所有被测化合物均对12株幽门螺杆菌临床菌株表现出有趣的抗菌活性,其中化合物> 4b 和> 4c的体外效果最佳。分数抑制浓度(FIC)平均值在第5组的所有化合物中均表现出协同模式。此外,与甲硝唑联用时,观察到某些第4组测试化合物的加合活性。相反,测试的化合物没有显示出明显的脲酶抑制活性。这些结果支持了新的氟喹诺酮衍生物与抗H结合使用的潜力。幽门螺杆菌药物治疗幽门螺杆菌相关疾病。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号